Last reviewed · How we verify
Midazolam sedation
Midazolam sedation is a Benzodiazepine Small molecule drug developed by University of Liege. It is currently FDA-approved for Procedural sedation and anxiolysis, Induction of general anesthesia, Acute anxiety and agitation.
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation and anxiolysis.
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation and anxiolysis. Used for Procedural sedation and anxiolysis, Induction of general anesthesia, Acute agitation and anxiety management.
At a glance
| Generic name | Midazolam sedation |
|---|---|
| Sponsor | University of Liege |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation |
| Phase | FDA-approved |
Mechanism of action
Midazolam binds to GABA-A receptors and potentiates the effect of the inhibitory neurotransmitter GABA, leading to increased chloride ion influx and neuronal hyperpolarization. This results in depression of the central nervous system, manifesting as sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. The drug is commonly used for procedural sedation and anesthesia induction due to its rapid onset and short duration of action.
Approved indications
- Procedural sedation and anxiolysis
- Induction of general anesthesia
- Acute anxiety and agitation
- Seizure management
Common side effects
- Respiratory depression
- Hypotension
- Oversedation
- Amnesia
- Paradoxical reaction (agitation, disinhibition)
- Headache
Key clinical trials
- HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids (NA)
- Comparison Of The Effects Of Regional Anesthesia On Brain And Carotid Artery Oxygenation In Shoulder Surgery (NA)
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Basic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia (NA)
- Characteristic Electroencephalogram of General Anesthesia
- Virtual Reality to Improve Patient Experience During Endoscopic Mucosal and Submucosal Resection (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Prospective IR-led Sedation Feasibility (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midazolam sedation CI brief — competitive landscape report
- Midazolam sedation updates RSS · CI watch RSS
- University of Liege portfolio CI
Frequently asked questions about Midazolam sedation
What is Midazolam sedation?
How does Midazolam sedation work?
What is Midazolam sedation used for?
Who makes Midazolam sedation?
What drug class is Midazolam sedation in?
What development phase is Midazolam sedation in?
What are the side effects of Midazolam sedation?
What does Midazolam sedation target?
Related
- Drug class: All Benzodiazepine drugs
- Target: All drugs targeting GABA-A receptor
- Manufacturer: University of Liege — full pipeline
- Therapeutic area: All drugs in Anesthesia/Sedation
- Indication: Drugs for Procedural sedation and anxiolysis
- Indication: Drugs for Induction of general anesthesia
- Indication: Drugs for Acute anxiety and agitation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing